Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics

[1]  Jianming Xu,et al.  Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China , 2018, Helicobacter.

[2]  Y. Yamaoka.  How to eliminate gastric cancer-related death worldwide? , 2018, Nature Reviews Clinical Oncology.

[3]  Yong Xie,et al.  Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta‐analysis , 2018, Helicobacter.

[4]  Z. Udwadia,et al.  Tuberculosis in South Asia: a tide in the affairs of men , 2018, Multidisciplinary Respiratory Medicine.

[5]  J. Raymond,et al.  Molecular characterization of Helicobacter pylori resistance to rifamycins , 2018, Helicobacter.

[6]  P. Khanal,et al.  Enteric Fever Caused by Salmonella enterica Serovars with Reduced Susceptibility of Fluoroquinolones at a Community Based Teaching Hospital of Nepal , 2017, International journal of microbiology.

[7]  T. Alarcón,et al.  Antibiotic resistance in Helicobacter pylori , 2017, Current opinion in infectious diseases.

[8]  R. Malekzadeh,et al.  Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran , 2017, Digestive Diseases and Sciences.

[9]  Juntaro Matsuzaki,et al.  Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients , 2017, United European gastroenterology journal.

[10]  Y. Yamaoka,et al.  Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal , 2016, BMC Microbiology.

[11]  Alimuddin Zumla,et al.  Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[12]  R. Hunt,et al.  Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report , 2016, Gut.

[13]  Jinfeng Dai,et al.  Helicobacter pylori and Antibiotic Resistance, A Continuing and Intractable Problem , 2016, Helicobacter.

[14]  L. Marzio,et al.  Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third‐Line Treatment of Helicobacter pylori Infection: Two Pilot Studies , 2016, Helicobacter.

[15]  J. Janda,et al.  Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. , 2016, Diagnostic microbiology and infectious disease.

[16]  Y. Yamaoka,et al.  Helicobacter pylori antibiotic susceptibility patterns in Bangladesh: Emerging levofloxacin resistance. , 2016, Journal of infection in developing countries.

[17]  Ningmin Yang,et al.  The Association of Age and Antibiotic Resistance of Helicobacter Pylori , 2016, Medicine.

[18]  S. Dixit,et al.  Antibiotic Use, Its Resistance in Nepal and Recommendations for Action: A Situation Analysis. , 2015, Journal of Nepal Health Research Council.

[19]  G. Jacoby,et al.  Mechanisms of drug resistance: quinolone resistance , 2015, Annals of the New York Academy of Sciences.

[20]  T. Furuta,et al.  High Helicobacter pylori cure rate with sitafloxacin‐based triple therapy , 2015, Alimentary pharmacology & therapeutics.

[21]  Christopher M. Parry,et al.  Antimicrobial Resistance , and Antimicrobial Management of Invasive Salmonella Infections , 2015 .

[22]  M. Dec,et al.  Antibiotic susceptibility of Lactobacillus strains isolated from domestic geese , 2015, British poultry science.

[23]  Lihua He,et al.  Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. , 2015, World journal of gastroenterology.

[24]  A. Gales,et al.  Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: Comparing agar dilution, E-test, and disk diffusion , 2014, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology].

[25]  S. Oveisi,et al.  Low Dose Furazolidone for Eradication of Helicobacter pylori Instead of Clarithromycin: A Clinical Trial , 2014, Global journal of health science.

[26]  Ji-Rong Wen,et al.  Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. , 2014, World journal of gastroenterology.

[27]  J. Hossain,et al.  The Quest for the Best Metric of Antibiotic Use and Its Correlation with the Emergence of Fluoroquinolone Resistance in Children , 2014, The Pediatric infectious disease journal.

[28]  R. Hunt,et al.  Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials , 2014, BMJ : British Medical Journal.

[29]  Y. Yamaoka,et al.  Extremely high prevalence of Helicobacter pylori infection in Bhutan. , 2013, World journal of gastroenterology.

[30]  M. D’Elios,et al.  Helicobacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen , 2012, Expert review of gastroenterology & hepatology.

[31]  H. Aftab,et al.  Observation of Gastric Mucosa in Bangladesh, the Country with the Lowest Incidence of Gastric Cancer, and Japan, the Country with the Highest Incidence , 2012, Helicobacter.

[32]  M. Sasatsu,et al.  Fluoroquinolone Resistance in Helicobacter pylori: Role of Mutations at Position 87 and 91 of GyrA on the Level of Resistance and Identification of a Resistance Conferring Mutation in GyrB , 2012, Helicobacter.

[33]  J. Gisbert,et al.  Review article: rifabutin in the treatment of refractory Helicobacter pylori infection , 2012, Alimentary pharmacology & therapeutics.

[34]  Yanlin Zhao,et al.  The Beginning of the rpoB Gene in Addition to the Rifampin Resistance Determination Region Might Be Needed for Identifying Rifampin/Rifabutin Cross-Resistance in Multidrug-Resistant Mycobacterium tuberculosis Isolates from Southern China , 2011, Journal of Clinical Microbiology.

[35]  T. Hibi,et al.  Helicobacter pylori Resistance to Rifabutin in the Last 7 Years , 2011, Antimicrobial Agents and Chemotherapy.

[36]  D. Graham,et al.  Helicobacter pylori infection in India from a western perspective , 2010, The Indian journal of medical research.

[37]  D. Graham,et al.  Helicobacter pylori treatment in the era of increasing antibiotic resistance , 2010, Gut.

[38]  K. Murakami,et al.  Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations , 2009, Antimicrobial Agents and Chemotherapy.

[39]  T. Hibi,et al.  Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation , 2009, Antimicrobial Agents and Chemotherapy.

[40]  M. Boffito,et al.  Journal of Antimicrobial Chemotherapy Advance Access published August 18, 2008 Journal of Antimicrobial Chemotherapy , 2022 .

[41]  Zhiqiang Liu,et al.  Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. , 2008, World journal of gastroenterology.

[42]  A. Flórez,et al.  Molecular Characterization of Intrinsic and Acquired Antibiotic Resistance in Lactic Acid Bacteria and Bifidobacteria , 2007, Journal of Molecular Microbiology and Biotechnology.

[43]  C. Beglinger,et al.  Long-Term Re-Infection Rate after Helicobacter pylori Eradication in Bangladeshi Adults , 2007, Digestion.

[44]  P. Shankar,et al.  Fluoroquinolone utilization among inpatients in a teaching hospital in western Nepal. , 2007, JPMA. The Journal of the Pakistan Medical Association.

[45]  I. Paulsen,et al.  Microbial drug efflux proteins of the major facilitator superfamily. , 2006, Current drug targets.

[46]  H. Dupont,et al.  Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  A. Gasbarrini,et al.  Eradication of Helicobacter pylori: Are Rifaximin-Based Regimens Effective? , 2006, Digestion.

[48]  G. Jacoby.  Mechanisms of resistance to quinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  B. D. de Jonge,et al.  Compound Efflux in Helicobacter pylori , 2005, Antimicrobial Agents and Chemotherapy.

[50]  C. Scarpignato,et al.  Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential , 2005, Chemotherapy.

[51]  Laura N. Gerard,et al.  Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections , 2005, Expert review of anti-infective therapy.

[52]  D. Gajjar,et al.  Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects , 2003, Antimicrobial Agents and Chemotherapy.

[53]  D. Graham,et al.  High-Level β-Lactam Resistance Associated with Acquired Multidrug Resistance in Helicobacter pylori , 2003, Antimicrobial Agents and Chemotherapy.

[54]  L. Valera,et al.  Antibacterial Spectrum of a Novel Des-Fluoro(6) Quinolone, BMS-284756 , 2000, Antimicrobial Agents and Chemotherapy.

[55]  N. Lehn,et al.  Mutations at Four Distinct Regions of the rpoB Gene Can Reduce the Susceptibility of Helicobacter pylorito Rifamycins , 2000, Antimicrobial Agents and Chemotherapy.

[56]  E. Bayerdörffer,et al.  Rifampin and Rifabutin Resistance Mechanism inHelicobacter pylori , 1999, Antimicrobial Agents and Chemotherapy.

[57]  K. Okita,et al.  In Vitro Anti-Helicobacter pyloriActivities of New Rifamycin Derivatives, KRM-1648 and KRM-1657 , 1999, Antimicrobial Agents and Chemotherapy.

[58]  L. Piddock.  Fluoroquinolone resistance , 1998, BMJ.

[59]  S. Suerbaum,et al.  Primary and Acquired Helicobacter pylori Resistance to Clarithromycin, Metronidazole, and Amoxicillin—Influence on Treatment Outcome , 1998, American Journal of Gastroenterology.

[60]  G. Barbara,et al.  Rifaximin and Helicobacter pylori eradication. , 1997, European review for medical and pharmacological sciences.

[61]  C. Kunin.  Antimicrobial activity of rifabutin. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  L. Barbara,et al.  The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. , 1995, The Journal of antimicrobial chemotherapy.

[63]  P. Olliaro,et al.  Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.

[64]  R. N. Brogden,et al.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. , 1994, Drugs.

[65]  D. Peters,et al.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. , 1992, Drugs.

[66]  J. Bříza.  IARC Monographs on tiie evaluation of the carcinogenic risk of chemicals to humans. volume 31. Some food additives, feed additives and naturally occurring substances. , 1984, Biologia Plantarum.

[67]  D. Graham,et al.  Furazolidone in Helicobacter Pylori Therapy: Misunderstood and Often Unfairly Maligned Drug Told in A Story of French Bread , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[68]  R. Hunt,et al.  World Gastroenterology Organisation Global Guideline: Helicobacter pylori in Developing Countries , 2011, Journal of digestive diseases.

[69]  P. Shcherbakov,et al.  [Rifaximin in combined treatment of the Helicobacter pylori infection in childhood]. , 2011, Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology.

[70]  H. Sumano,et al.  Evaluation of the carcinogenic effects of furazolidone and its metabolites in two fish species , 2004, The Pharmacogenomics Journal.

[71]  EUCAST Definitive Document E.DEF 3.1, June 2000: Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[72]  Peter J. Schaap,et al.  Molecular characterization of the , 1997 .

[73]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.